Skip to main
ICUI
ICUI logo

ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical (ICUI) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ICU Medical's strong market position as a leader in infusion therapy, bolstered by strategic acquisitions, facilitates a compelling outlook for its financial performance. The company is at the beginning of a new product and pump replacement cycle, which is anticipated to drive revenue growth exceeding 100 basis points, along with an improvement in gross margins by nearly 50 basis points and an EBITDA margin rising above 20%. With a cleaner business structure and enhanced financial profile, ICU Medical could command higher valuation multiples than its current standing, making it an attractive prospect within the medtech sector.

Bears say

ICU Medical faces a significant negative outlook due to its anticipated removal of approximately $35 million in annual EBITDA contribution, which could reduce its leverage below 2x, raising concerns about financial stability and operational efficiency. The profitability of its Vital Care segment is notably weaker, with gross margins (GM%) estimated to be 300-400 basis points lower than its other segments, Consumables and Infusion Systems. This margin disparity suggests potential inefficiencies and underperformance within the Vital Care division, complicating the overall financial attractiveness of ICU Medical amidst ongoing operational challenges.

ICU Medical (ICUI) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICU Medical (ICUI) Forecast

Analysts have given ICU Medical (ICUI) a Buy based on their latest research and market trends.

According to 3 analysts, ICU Medical (ICUI) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICU Medical (ICUI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.